KCC2 Inhibitors for Age-Related Cognitive Decline

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for new compounds capable of mitigating age-related cognitive decline unrelated to a neurodegenerative disease, as current treatments are lacking.

Innovation Solution

The use of KCC2 inhibitors, such as furosemide, to regulate chloride ion concentration in neurons, addressing the hyper-inhibitory phenotype associated with age-related cognitive decline.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If KCC2 expression increases with aging, then chloride extrusion capacity improves, but hyper-inhibitory GABAergic signaling and cognitive decline occur

Engineering Contradiction:

Improvechloride homeostasisVSAvoidhyper-inhibitory phenotype

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies parameter changes by using KCC2 inhibitors (furosemide, bumetanide) to modulate the expression level and activity of KCC2 transporter. By changing the inhibitory parameter of KCC2, the patent restores chloride homeostasis and normalizes GABAergic signaling in aged brains, thereby treating cognitive decline without completely eliminating KCC2 function.

Inventive Principle:

Principle #35Parameter changes

2Stability of the object's composition

If KCC2 transporter activity increases to maintain chloride homeostasis, then neuronal chloride concentration is regulated, but cognitive functions deteriorate due to hyper-inhibition

Engineering Contradiction:

Improvechloride concentrationVSAvoidcognitive function

Core Design Contradiction:

Stability of the object's compositionVSProductivity

Solution Approach 1:

The patent implements feedback control by using KCC2 inhibitors to counteract the age-related overactivity of KCC2. The inhibitors provide negative feedback to reduce excessive chloride extrusion, thereby normalizing GABAergic inhibition and improving cognitive function while maintaining adequate chloride homeostasis.

Inventive Principle:

Principle #23Feedback

3Adaptability or versatility

If no specific pharmacological treatment is available for age-related cognitive decline, then preventive strategies are limited to lifestyle changes, but effective treatment options are lacking

Engineering Contradiction:

Improvepreventive strategiesVSAvoidpharmacological treatment

Core Design Contradiction:

Adaptability or versatilityVSEase of manufacture

Solution Approach 1:

The patent applies universality by demonstrating that existing KCC2 inhibitors (furosemide, bumetanide), originally developed for other indications, can be repurposed to treat age-related cognitive decline. This multi-functional use of known compounds provides an effective pharmacological treatment without requiring development of entirely new drugs.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

KCC2 inhibitors like furosemide restore normal GABAergic signaling and improve cognitive functions in elderly individuals by reducing oversedation and enhancing memory performance.

Implementation Method 1

The main regulators of Cl− homeostasis in neurons are the NKCC1 cotransporter (Cl− importer) and the KCC2 transporter (Cl− exporter)

Methodology Applied

Scientific EffectIon transport:

Implementation Method 2

KCC2 inhibitors, such as furosemide, to regulate chloride ion concentration in neurons

Methodology Applied

Scientific EffectInhibitor blocking:

Data Source

PatentUS20250275987A1Modulators of intracellular chloride concentration for use in the treatment of cognitive decline

Publication Date: 2025.09.04 FOND INST ITAL DI TECH

AI summary

The present invention relates to KCC2 inhibitors for the use in the treatment of age-related cognitive decline unrelated to a neurodegenerative disease. In particular, compounds of formula (I), among which furosemide, are provided.